Avenzo Therapeutics
Avenzo Therapeutics is a clinical-stage biotechnology company developing next-generation oncology therapies. Their lead drug candidate, AVZO-021, is a CDK2 inhibitor currently in Phase 1 trials for advanced solid tumors and combinations in HR+/HER2-negative metastatic breast cancer. The company also has an exclusive option agreement for a potential first-in-class Nectin4/TROP2 bispecific antibody-drug conjugate.
Buy Funded Startups lists
Funding Round: Series A1
Funding Amount: $386M
Date: 18-Nov-2024
Investors: OrbiMed, Foresite Capital, SR One, Lilly Asia Ventures, Surveyor Capital, New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital, three new investors
Markets: Oncology, Biotechnology
HQ: San Diego, California, United States
Founded: 2022
Website: http://www.avenzotx.com/
LinkedIn: https://www.linkedin.com/company/avenzotx
Crunchbase: https://www.crunchbase.com/organization/avenzo-therapeutics
Leave a Comment
Comments
No comments yet.